文献速递毛发、甲与色素性疾病

巴瑞替尼持续治疗重度斑秃三年维持长期疗效:BRAVE-AA1与BRAVE-AA2研究

Maintenance of long-term efficacy with continuous baricitinib treatment in patients with severe alopecia areata: 3-year results from BRAVE-AA1 and BRAVE-AA2.
PubMed 文献 · J Am Acad Dermatol · 2025-11-26

基于BRAVE-AA1和BRAVE-AA2两项3期随机双盲试验,分析第52周达到SALT评分≤20的重度斑秃成人患者继续相同剂量巴瑞替尼治疗至152周的疗效与安全性。结果显示,4mg组89.1%(115/129)和2mg组83.6%(56/67)的患者维持SALT评分≤20,特别关注不良事件发生率与早期安全性报告一致,无新安全信号。

要点

  • 第52周应答者继续巴瑞替尼治疗至152周,4mg组89.1%维持SALT≤20。
  • 2mg组83.6%的患者在152周维持SALT≤20。
  • 长期治疗可持续维持和扩展头皮、眉毛及睫毛的毛发再生。

核心结论

  • 持续巴瑞替尼治疗152周可稳定维持并扩展重度斑秃患者的毛发再生,且无新安全信号。

研究设计与样本

  • 分析纳入BRAVE-AA1和BRAVE-AA2两项3期随机双盲临床试验中SALT评分≥50的成人重度斑秃患者。
  • 仅纳入第52周达到SALT评分≤20的应答者,继续相同剂量巴瑞替尼治疗至152周。

主要发现

  • 巴瑞替尼4mg组第52周应答者中115/129(89.1%)在152周维持SALT评分≤20。
  • 巴瑞替尼2mg组第52周应答者中56/67(83.6%)在152周维持SALT评分≤20。
  • 特别关注不良事件发生率与早期安全性报告相比保持一致。

关键数值与推荐

  • 维持应答定义为第152周SALT评分≤20。
  • 4mg组维持应答比例89.1%(115/129),2mg组83.6%(56/67)。

临床怎么用

  • 对巴瑞替尼治疗第52周达到SALT≤20的重度斑秃患者,继续相同剂量治疗可长期维持疗效。
  • 长期治疗期间安全性特征与已知报告一致,无需新增监测措施。

局限性

  • 分析未纳入第52周未达到SALT≤20但继续治疗患者的结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Baricitinib, a Janus kinase inhibitor with an established safety profile across multiple indications, has demonstrated efficacy in the treatment of severe alopecia areata with high maintenance of response during the initial treatment extension period. OBJECTIVES: To evaluate efficacy and safety of baricitinib for adults with severe alopecia areata through 152 weeks of continuous therapy. METHODS: The analysis includes patients from the BRAVE-AA1 and BRAVE-AA2 phase 3, randomized, double-blind, clinical trials: adults with Severity of Alopecia Tool (SALT) scores ≥50 who achieved SALT score ≤20 at week 52 (responders) and were continued on the same dose of baricitinib up to 152 weeks. RESULTS: Among week 52 responders who were continuously treated with baricitinib 4 mg or baricitinib 2 mg, 115 of 129 (89.1%) and 56 of 67 (83.6%), respectively, maintained SALT score ≤20 at week 152. The incidence rate of adverse events of special interest relative to earlier safety reports, remained consistent. LIMITATIONS: The analysis does not include outcomes of patients without SALT score ≤20 response at week 52, who continued therapy post-week 52. CONCLUSIONS: Over 152 weeks, patients stably maintained and extended their regrowth across scalp, eyebrows, and eyelashes with continued baricitinib treatment. There were no new safety signals.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Senna M, Mostaghimi A, Sinclair R, et al. Maintenance of long-term efficacy with continuous baricitinib treatment in patients with severe alopecia areata: 3-year results from BRAVE-AA1 and BRAVE-AA2. J Am Acad Dermatol. 2025. PMID: 41314424. doi:10.1016/j.jaad.2025.11.064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。